Introduction

RCAS1 (receptor binding cancer antigen expressed on
SiSo cells) was isolated as a cDNA encoding the antigen recognized by 22-1-1 antibody that was produced from mice immunized with the human uterine cervical adenocarcinoma cell line, SiSo [1, 2] . The anti-RCAS1 monoclonal antibody strongly stained human uterine and ovarian carcinomas [3] [4] [5] . In nongynecological carcinomas, RCAS1 is also expressed in nonsmall-cell lung carcinomas, hepatocellular carcinomas, and squamous cell carcinomas of the skin [6] [7] [8] . In vitro studies of RCAS1 indicated that it might function as an apoptosisinducing factor, because binding between RCAS1 and its receptor induced apoptosis in receptor-expressing cells, including peripheral lymphocytes, such as T, B, and natural killer cells. Thus, RCAS1 was recognized to play a role in the immune evasion of tumor cells. Recent studies revealed that RCAS1 existed not only in neoplastic cells but also in cells in normal tissues, and that it controlled immune response [9] [10] [11] .
Ropponen et al. [12] have reported that several human neoplasms contain many lymphocytes that infiltrate the center and periphery of the tumor, and they defined these lymphocytes as tumor-infiltrating lymphocytes (TILs). Moreover, the number of TILs was found to correlate with survival in colorectal and esophageal carcinoma patients [12, 13] . Setälä et al. [14] investigated the prognostic value of various clinicopathological factors in 321 gastric carcinoma patients. In their study, the density of lymphocytes and plasma cells was not an independent prognostic predictor on multivariate analysis, despite its power on univariate analysis. On the other hand, gastric carcinoma with lymphoid stroma, infiltrated uniformly with an abundance of lymphocytes and plasma cells throughout the entire area of the tumor, is known to show an extremely high survival rate [15] . It has been reported that Fas and Fas ligand (FasL) induce apoptotic cell death of TILs in melanomas [16] .
This apoptotic depletion of TILs by tumor cells has been suggested to cause tumor immune evasion [17] [18] [19] [20] . However, data on the relationship between RCAS1 and the apoptosis of TILs in gastric carcinoma are scarce.
In the present study, the expression of RCAS1 and the numbers of TILs in advanced gastric carcinomas were examined. We attempted to elucidate the relationship between RCAS1, TILs, clinicopathological variables, and postoperative survival rates. Finally, the relationship between RCAS1 expression and the apoptosis of TILs was investigated to clarify the mechanisms of immune evasion in human gastric carcinoma.
Patients and methods
Patients
A total of 129 patients (75 men and 54 women; mean age Ϯ SD, 59 Ϯ 13 years; range, 31-91 years) with primary gastric adenocarcinomas invading the serosa (T3 gastric carcinoma) underwent curative surgery between 1986 and 1992 at the First Department of Surgery, Tottori University Hospital. None of the patients had received preoperative adjuvant therapy. The clinicopathological findings were determined according to the Japanese classification of gastric carcinoma [21] . The criteria considered for curative resection were the complete removal of a primary gastric tumor, dissection of the regional lymph nodes, and no remaining macroscopic tumors. These patients had no metastases in the liver, or peritoneum, or in other distant organs at the time of surgery. No other previous or concomitant primary cancer was present. All had had either distal partial gastrectomy, proximal gastrectomy, or total gastrectomy with regional lymph node dissection to group 1 (D1), group 2 (D2), and group 3 (D3) excluding the paraaortic nodes, with curative intent. None of the resection margins were positive for tumors. Most patients received postoperative chemotherapy with the consecutive administration of uracil/tegafur, orally, at a dose of 300 mg daily for 1 year after surgery. However, some patients refused or discontinued chemotherapy. The patients were periodically checked by diagnostic imagings (chest X-ray, double-contrast barium meal study, upper gastrointestinal fiberscopy, ultrasonography, and computed tomography) for early detection of recurrence. All of the patients were followed for at least 5 years.
RCAS1
For immunohistochemical analysis, streptavidin-biotin methodology (Histofine SAB-PO kit; Nichirei, Tokyo, Japan) was used for formalin-fixed and paraffin-embedded specimens. Sections (4-µm) sections were cut from paraffin-embedded blocks. Tissue sections were deparaffinized and rehydrated in serial ethanol solutions. After repeated washing with phosphate buffered saline (PBS), the sections were treated with proteinase K (Dako, Glostrup, Denmark) for 3 min. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in methanol for 10 min. Tissue sections were then washed twice with PBS and preblocked for 10 min with 10% rabbit serum. Specimens were incubated overnight at 4°C with anti-RCAS1 monoclonal antibody (dilution, 1 : 500; Medical and Biological Laboratories, Nagoya, Japan). Sections were washed three times in PBS and incubated with the secondary antimouse immunoglobulin (IgG ϩ IgA ϩ IgM) conjugated with biotin (Nichirei) for 30 min, followed by incubation with streptavidin-peroxidase complex (Nichirei) for 30 min. After three additional washes in PBS, diaminobenzidine tetrahydrochloride working solution was applied. Finally, the slides were counterstained in hematoxylin. To examine the specificity of immunostaining, the primary antibody was replaced by normal mouse IgM. Tissue sections with more than 5% reactive tumor cells were defined as positive. The staining pattern was classified as follows: negative, less than 5% of reactive tumor cells; 1ϩ, weak (positive carcinoma cells were detected in 5%-25%); 2ϩ, moderate (positive carcinoma cells were detected in 25%-50%); and 3ϩ, strong (positive carcinoma cells were detected in Ͼ50%). All of the histological slides were examined by two observers (S.T. and Y.M.), who were unaware of the clinical data or the disease outcome. When the interpretation differed between the two observers, reevaluation was done, for a final decision on a conference microscope.
TILs
In addition to the examination of hematoxylin-and eosin-stained sections, lymphocyte infiltration into tumors was examined immunohistochemically using the anti-human T lymphocyte antibody (UCHL-1; Nichirei) in serial sections. UCHL-1 labeled resting T cells within both the CD4 and CD8 subsets and mature activated T cells. The immunostaining was performed as described above, except for the use of proteinase K. As a negative control, normal mouse IgG was used in place of UCHL-1 at the same concentration. To identify nuclei with DNA strand break at a cellular level, anti-single-strand DNA (ssDNA) polyclonal antibody (dilution, 1 : 100; Dako Japan, Kyoto, Japan) was used. Immunostaining was done using the Envisionϩ kit (Dako, Carpinteria, CA, USA) by the dextran polymer method, according to the manufacturer's instructions. Border fields between gastric carcinoma and normal gland, which were observed under a microscope (magnification, ϫ200), were randomly selected in each section. The degree of TIL infiltration was divided into the following two groups: marked infiltration, TILs infiltrated diffusely in the stroma of the tumor or around the tumor; and slight infiltration, TILs scattered in the stroma of the tumor or around the tumor. After detection of UCHL-1-positive TILs, at least five areas per slide were examined to count 1000 TILs and the number of ssDNA-positive apoptotic cells in serial sections. The results were defined as the apoptosis index (AI; the number of ssDNA-positive cells among 1000 TILs). The evaluation was done by two observers, as described above.
Statistical analysis
Statistical analysis included the standard 2 test, MannWhitney U-test, and Kruskal-Wallis test. The survival rates were estimated by the Kaplan-Meier method, and statistically significant differences between survival curves were examined by the log-rank test. On multivariate analysis, independent prognostic factors were determined by the Cox proportional hazards model (StatView 5.0; Abacus Concepts, Berkeley, CA, USA). P Ͻ 0.05 was regarded as statistically significant.
Results
Immunohistochemistry
RCAS1 protein existed both in the membrane and cytoplasm of tumor cells (Fig. 1a) . Moreover, RCAS1 was very weakly but diffusely detected in the normal mucosal cells. RCAS1 staining in normal tissues was found more predominantly in the superficial layer than in the basal layer. The expression of RCAS1 in tumor cells was demonstrated in 70 patients (54.3%). Following the previous report, we defined 25% of RCAS1-positivestaining cells in tumor cells as the cutoff value for low (negative/1ϩ) and high (2ϩ/3ϩ) expression. Of the 129 patients, 33 (25.6%) showed high expression of RCAS1 protein (2ϩ in 18 and 3ϩ in 15), whereas 96 (74.4%) demonstrated low expression (negative in 59 and 1ϩ in 37).
Clinicopathological analysis
The relationship between RCAS1 expression and clinicopathological variables in T3 gastric carcinomas is shown in Table 1 . There were significant correlations between RCAS1 expression and histological type of carcinoma or lymph node metastasis. High RCAS1 expression was more frequently observed in the undifferentiated type and in patients with N2 lymph node metastasis. In contrast, no significant correlation was detected between RCAS1 expression and age, sex, tumor size, or lymphatic-vascular space invasion.
TILs
Immunohistochemistry of TILs revealed that 74 patients had marked infiltration and 55 had slight infiltration. We investigated the relationship between infiltration and apoptosis in TILs (Fig. 1b) . Tumors with slight TIL infiltration demonstrated significantly more frequent apoptosis in TILs (AI, 9.2 Ϯ 7.2) than those with marked TIL infiltration (AI, 7.1 Ϯ 5.6; P Ͻ 0.05, Student's t-test). Furthermore, we analyzed the rate of apoptosis in TILs based on RCAS1 expression. Apoptosis of TILs was more frequent in tumors with high RCAS1 expression (AI, 9.5 Ϯ 7.0) than in those with low RCAS1 expression (AI, 7.5 Ϯ 6.2), with a marginally significant difference (P ϭ 0.057; Fig. 2) . Table 2 shows a detailed analysis of apoptosis in TILs. In patients with slight TIL infiltration, significantly higher rates of apoptosis were observed in RCAS1-positive tumors than in RCAS1-negative tumors. However, the expression of RCAS1 did not affect the apoptosis in tumors with marked TIL infiltration. When tumors were 8 cm or more in diameter, there was no difference in the rate of apoptosis between tumors with high and low RCAS1 expression. In patients with tumors less than 8 cm in diameter, however, apoptosis was significantly more frequent in tumors with high RCAS1 expression than in those with low RCAS1 expression. Moreover, there was a marginally significant difference in the rate of apoptosis between tumors with high and low RCAS1 expression in patients with lymph node metastasis. In patients with no lymph node metastasis, however, there was no relationship between RCAS1 expression and the rate of apoptosis in TILs.
Survival of patients
The estimated 5-year overall survival rates of patients with low and high RCAS1 expression were 77.9% and 48.4%, respectively (Fig. 3) . Patients with high RCAS1 expression had significantly worse overall survival than those with low RCAS1 expression (P Ͻ 0.01). Table 3 shows the results of multivariate analysis for the 129 patients. The covariates included in the model were age and sex of patients, tumor size, histologic classification, lymph node metastasis, lymphatic invasion, venous in- vasion, and the RCAS1 expression. RCAS1 expression, as well as tumor size and lymph node metastasis, was recognized as an independent prognostic factor. Therefore, the clinical significance of RCAS1 expression was further analyzed based on the characteristics of tumors (Figs. 4, 5) . The prognosis of patients with high RCAS1 expression was significantly poorer than that of those with low RCAS1 expression, when tumors were less than 8 cm in diameter or involved the regional lymph nodes. However, such a relationship was not observed in patients with tumor 8 cm or more in diameter or with no lymph node metastasis. There was a significant difference in survival between patients with high and low RCAS1 expression in patients with histologically undifferentiated type. The patients did not provide sufficient data for analysis, because of the small number of patients with high RCAS1 expression. There was no significant difference in survival between patients with marked and slight infiltration of TILs. However, the 5-year survival rates of patients with rare and frequent apoptosis in TILs were 76.5% and 55.7%, respectively. Patients with rare apoptosis in TILs survived significantly longer than those with frequent apoptosis in TILs (P Ͻ 0.05). RCAS1 expression significantly correlated with poor prognosis in patients with TILs exhibiting frequent apoptosis (P Ͻ 0.05), whereas there was no prognostic difference between RCAS1 expression levels in patients with a low rate of apoptosis in TILs (Fig. 6 ).
Discussion
Nakashima et al. [2] found that RCAS1 inhibited the in vitro growth of its receptor-expressing cells and induced apoptotic cells. Moreover, when freshly isolated peripheral blood lymphocytes (PBLs) were co-cultured with RCAS1 protein, the growth of lymphocytes was suppressed. This inhibition of cell growth was more significant in CD3-positive cells than in normal PBLs. Given these facts, tumor cells were thought to attack the immune cells by expressing RCAS1. As for the function of RCAS1 to induce apoptosis in TILs in vivo, Iwasaki et al. [6] proved that the apoptosis rate of TILs in lung carcinoma patients with high RCAS1 expression was higher than that in those with low expression, by using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method. Therefore, we investigated, in the present study, the relationship between RCAS1 expression and apoptosis in TILs in gastric carcinoma.
Immunohistochemical studies showed that various kinds of carcinoma expressed RCAS1 protein on the tumor cells at high rates; 87.5% in adenocarcinoma of the uterine cervix, 82.6% in invasive squamous cell carcinoma of the uterine cervix, 74.2% in lung carcinomas of various histologic types, and 73.8% in squamous cell carcinomas of the skin [3] [4] [5] [6] [7] [8] . Recently, Kubokawa et al. [22] reported that RCAS1 was detected in 98.4% of gastric carcinomas. In the current series, however, RCAS1 was detected in 54.3% (70/129) of patients with gastric carcinoma invading the serosa. In addition, high expression was observed in 25.6% of patients. This   Fig. 4a,b . Kaplan-Meier survival curves for patients with T3 gastric carcinoma less than 8 cm in diameter (a), and 8 cm or more in diameter (b). In the patients with tumors less than 8 cm in diameter, the prognosis of patients with high RCAS1 expression was significantly poorer than that of those with low expression. N.S., Not significant Fig. 5a,b . Kaplan-Meier survival curves for patients with T3 gastric carcinoma with lymph node metastasis (a), and no metastasis (b). In the patients with lymph node metastasis, the prognosis of patients with high RCAS1 expression was significantly poorer than that of those with low expression difference may be due to differences in the methods of preservation of the specimen and antigen retrieval. Kubokawa et al. [22] used a universal immunoenzyme polymer (UIP) method without antigen retrieval, while a streptavidin-biotin (SAB) method with proteinase K antigen retrieval was used in the current study.
RCAS1 was also detected in normal mucosal cells of the stomach, especially in the superficial layer. This finding is consistent with the report by Kubokawa et al. [22] . It was reported that RCAS1 existed in normal uterine endometrial cells and in normal ciliated columnar epithelial cells of the lung at low levels [3, 6, 11] . Moreover, recent evidence shows that RCAS1, which is mainly produced by macrophages in hematopoietic tissue, may have a crucial role in regulating erythropoiesis by modulating apoptosis of erythroid progenitor cells [10] . It is necessary to investigate the biological functions of RCAS1 expression in nontumorous tissue.
TILs participate in tumor growth control not only through T-cell cytotoxity but also by producing soluble mediators [23] . The majority of TILs in human tumors consist of T cells, suggesting an activation of the host defense mechanism [24] . Tumor-host interactions have been shown to play a significant role in predicting the disease outcome in several human tumors [24] [25] [26] . Furthermore, the human immune system can recognize many tumor-associated antigens, such as the MAGEfamily, p53, MUC-1, HER2/neu, and p21 ras [27] [28] [29] . Despite these antitumor mechanisms, the immune system often fails to inhibit tumor growth. In the current series, there was no significant difference in survival between patients with marked and slight infiltration of TILs. The reasons for this failure in tumor immunity might be insufficient expression of co-stimulatory or adhesion molecules by tumor cells, or defective processing and presentation of antigens on their cell surface [30] [31] [32] . Previous studies suggested that gastric carcinoma may require a greater number of TILs to overcome tumor growth than colorectal or esophageal carcinoma [12] [13] [14] [15] . The current study was carried out to elucidate the multiple steps by which gastric carcinoma escapes from immunological defense mechanisms. Patients with frequent apoptosis in TILs had a significantly poorer prognosis than those with rare apoptosis in TILs.
Tumor cells may also escape from immune surveillance by expressing FasL or other molecules that induce apoptosis in activated T cells [15, [33] [34] [35] . Similarly to the Fas-FasL system, RCAS1 inhibited the in vitro growth of lymphocytes expressing its receptor and induced apoptotic cell death, probably through the activation of interleukin (IL)-1 converting enzyme-like proteases [2] . In the present study, TILs in tumors with high RCAS1 expression demonstrated a higher AI than those with low expression, with a marginally significant difference. Apoptosis of TILs was more frequent in tumors with high RCAS1 expression than in those with low RCAS1 expression when tumors demonstrated slight TIL infiltration, smaller size, and lymph node metastases. These results suggest that RCAS1 expressed on tumor cells may induce apoptosis in lymphocytes positive for its receptor under certain conditions of tumor progression and thus contribute to tumor escape from the immune surveillance.
High RCAS1 expression was detected significantly more often in patients with N2 lymph node metastasis than in those with N0/N1 lymph node metastasis. This result was consistent with previous findings that RCAS1 expression was correlated with tumor progression [4, [6] [7] [8] 11] . Multivariate analysis revealed that RCAS1, as well as tumor size and lymph node metastasis, was an independent prognostic factor. Moreover, patients with low RCAS1 expression survived significantly longer than those with high expression when apoptosis frequently occurred in TILs. Therefore, the clinical significance of RCAS1 expression may be related to tumor progression and TIL infiltration. The finding that RCAS1 expressed in tumor cells may not induce apoptosis in TILs in the situation of marked TIL infiltration suggests a way to overcome the immune escape by RCAS1.
In the current study, we investigated the expression of RCAS1 in gastric carcinomas with serosal invasion. RCAS1 expression correlated with lymph node metastasis and with the histologic type of tumor. Moreover, high RCAS1 expression induced marginally more frequent apoptosis of the TILs than low expression. Thus, it was suspected that tumor cells escaped from the immune system by expressing RCAS1, which induced apoptosis in the RCAS1-positive T cells. RCAS1 expression was an independent prognostic factor in the patients with advanced gastric carcinoma. In view of these findings, anti-RCAS1 antibody might be a useful tool for determining the prognosis or biological characteristics of advanced gastric carcinoma. Further investigation of the RCAS1 apoptotic TIL interaction might be valuable in developing novel immunotherapy for advanced gastric carcinomas.
